GSK
1,795.00 GBpChange from previous close: −2.02%Absolute change: −37.00 GBp
At a glance
- Revenue growth
- +4.11%
- 2025 vs 2024
- Net income growth
- +121.98%
- 2025 vs 2024
- Net margin
- 17.5%
- 2024: 8.2%
Financial data
Amounts in millions of GBP; per-share values in GBP; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 32,667 | 31,376 | 30,328 | 29,324 | 24,696 |
| Cost of revenue | 8,947 | 8,845 | 8,388 | 9,407 | 8,033 |
| Gross profit | 23,720 | 22,531 | 21,940 | 19,917 | 16,663 |
| Selling, general and administrative | 9,013 | 10,847 | 9,156 | 8,179 | 6,784 |
| Research and development | 6,654 | 6,078 | 5,823 | 5,153 | 4,627 |
| Operating income | 9,447 | 6,190 | 8,403 | 7,322 | 5,634 |
| EBIT | 9,447 | 6,190 | 8,403 | 7,322 | 5,634 |
| EBITDA | 11,335 | 8,319 | 10,507 | 9,293 | 7,756 |
| Interest expense | 658 | 615 | 710 | 819 | 762 |
| Pre-tax income | 7,401 | 3,477 | 6,064 | 5,628 | 3,599 |
| Income tax | 1,112 | 526 | 756 | 707 | 83.0 |
| Net income | 5,716 | 2,575 | 4,928 | 14,956 | 4,385 |
| Net income to common shareholders | 5,716 | 2,575 | 4,928 | 14,956 | 4,385 |
| Basic EPS | 1.41 | 0.63 | 1.22 | 3.71 | 1.10 |
| Diluted EPS | 1.39 | 0.62 | 1.20 | 3.66 | 1.08 |
| Average shares (basic) | 4,051 | 4,077 | 4,052 | 4,026 | 4,003 |
| Average shares (diluted) | 4,117 | 4,142 | 4,111 | 4,084 | 4,052 |
| Dividend per share | 0.66 | 0.61 | 0.58 | 0.61 | 1.00 |